Dose Insider / Analyses / Ozempic vs Zepbound

Ozempic vs ZepboundDifferent Drugs, Different Approved Uses, and What the Head-to-Head Trials Found

Updated November 20, 2026 · 32 min read · FDA labels 2026, SURPASS-2, SURMOUNT-5

Ozempic and Zepbound are different drugs from different companies.

20.2% · 13.7%average weight lost on tirzepatide and on semaglutide in the 72-week head-to-head obesity trial
Average weight lost in 72 weeksHead-to-head obesity trial, % of starting weightTirzepatide20.2%Semaglutide13.7%Average weight lost in 72weeksHead-to-head obesity trial, % of starting weightTirzepatide20.2%Semaglutide13.7%

Tirzepatide is the drug in Zepbound and semaglutide the drug in Ozempic.

On this page

Ozempic is semaglutide, approved for adults with type 2 diabetes: for blood sugar, for cardiovascular risk and for kidney disease. Zepbound is tirzepatide, approved for adults to reduce weight and to treat obstructive sleep apnea with obesity. The two molecules have been compared directly twice, and tirzepatide produced more weight loss both times.

This page sets the two labels side by side: the approved uses, the two head-to-head trials, what each product did in its own trials, side effects, low blood sugar, the dose ladders on your calendar, and the prices on November 20, 2026.1,2

Are Ozempic and Zepbound the same kind of drug?

They are related and not identical. Semaglutide, the drug in Ozempic, activates one receptor, the receptor for the hormone GLP-1. Tirzepatide, the drug in Zepbound, activates two: the GLP-1 receptor and the receptor for a second hormone, GIP.1,2

The Zepbound label explains the second target cautiously: GLP-1 is a regulator of appetite and food intake, and nonclinical studies suggest that adding GIP may contribute further to the regulation of food intake.2 Both drugs are injected once a week.

OzempicZepbound
DrugSemaglutideTirzepatide
Acts onGLP-1 receptorGIP and GLP-1 receptors
MakerNovo NordiskEli Lilly
Approved forType 2 diabetes: blood sugar, cardiovascular risk, kidney diseaseWeight reduction; obstructive sleep apnea with obesity
Doses0.25, 0.5, 1, 2 mg2.5, 5, 7.5, 10, 12.5, 15 mg
How oftenOnce a weekOnce a week
Half-lifeAbout 1 weekAbout 5 days
Self-pay price$349 a month up to 1 mg, $499 for 2 mg$299 to $449 a month

Ozempic and Zepbound prescribing information; manufacturer price pages read November 20, 2026.1,2,5,6

The same two molecules are sold under other names for the other use. Semaglutide for weight is Wegovy, and tirzepatide for diabetes is Mounjaro.8,9 That is why comparing Ozempic with Zepbound means comparing a diabetes label with a weight label, and why the pages on Ozempic vs Wegovy and Mounjaro vs Zepbound matter here.

How do the four brand names fit together?

Two molecules, each sold under two names, one for diabetes and one for weight. Seeing all four at once explains most of the confusion between Ozempic and Zepbound.1,2,8,9

For type 2 diabetesFor weight
Semaglutide, Novo NordiskOzempic, up to 2 mgWegovy, 2.4 mg and up to 7.2 mg
Tirzepatide, Eli LillyMounjaro, up to 15 mgZepbound, up to 15 mg

Each pair has its own evidence. In its main label trial Wegovy 2.4 mg produced 14.9% weight loss over 68 weeks, against 2.4% on placebo.8 In its label trial as the only diabetes medicine, Mounjaro lowered HbA1c by 1.7 to 1.8 points over 40 weeks, against 0.1 on placebo, with 6.3 to 7.8 kg of weight loss.9

So a comparison of Ozempic with Zepbound crosses both lines of the table at once: a different molecule and a different use. The like-for-like comparisons are along the rows and down the columns, and the two direct trials above are the columns.

What exactly is each approved for?

Ozempic has three approved uses, all in adults with type 2 diabetes.1

Zepbound has two, each combined with a reduced-calorie diet and increased physical activity.2

Neither list contains the other's main use. Ozempic is not approved for weight reduction, and Zepbound is not approved for blood sugar control. A person with type 2 diabetes and obesity fits both labels, and one of Zepbound's main trials enrolled that group.2

SituationLabel that names it
Type 2 diabetes, blood sugar controlOzempic
Type 2 diabetes with cardiovascular diseaseOzempic
Type 2 diabetes with chronic kidney diseaseOzempic
Obesity, or overweight with a weight-related conditionZepbound
Moderate to severe obstructive sleep apnea with obesityZepbound

What each product is approved for. It is not a recommendation.1,2

Have semaglutide and tirzepatide been compared directly?

Twice, once in diabetes and once in obesity. Neither trial used the brand names as this page does, so it helps to say exactly which doses were tested.3,4

SURPASS-2SURMOUNT-5
Who1,879 adults with type 2 diabetes on metformin751 adults with obesity, without diabetes
Length40 weeks72 weeks
Semaglutide dose1 mg, a dose of Ozempic1.7 or 2.4 mg, doses of Wegovy
Tirzepatide dose5, 10 or 15 mg10 or 15 mg
Weight, semaglutide−5.7 kg−13.7%
Weight, tirzepatide−7.6, −9.3 and −11.2 kg−20.2%
HbA1c, semaglutide−1.9 pointsNot the question
HbA1c, tirzepatide−2.0, −2.2 and −2.3 pointsNot the question

Frías 2021 and Aronne 2025.3,4

The two direct trialsSURPASS-2, SURMOUNT-5
Trial

The obesity trial reports percent of body weight; the diabetes trial reports kilograms in people who averaged about 94 kg. The obesity trial was open-label and funded by the maker of tirzepatide.

The people in the diabetes trial started with an average HbA1c of 8.3% and an average weight of about 94 kg.3

In the diabetes trial the difference in blood sugar was small and the difference in weight grew with the dose: 1.9 kg more than semaglutide on 5 mg, 3.6 kg more on 10 mg and 5.5 kg more on 15 mg. At the end, 79% of people on semaglutide and 82% to 86% on tirzepatide had an HbA1c below 7%.3

In the obesity trial people were brought to the highest dose they could tolerate. Weight fell 20.2% on tirzepatide and 13.7% on semaglutide, and waist circumference 18.4 cm against 13.0 cm.4

What else the two direct trials reported

Both trials were open-label: participants and doctors knew which drug was being taken.3,4 In the diabetes trial people were assigned in equal numbers to the four groups, and blood sugar below 54 mg/dL was reported by 0.4% on semaglutide and by 0.6%, 0.2% and 1.7% on tirzepatide 5, 10 and 15 mg.3

In the obesity trial, people on tirzepatide were more likely than those on semaglutide to lose at least 10%, 15%, 20% and 25% of their weight. The most common adverse events in both groups were in the stomach and gut, most were mild to moderate, and they occurred mainly while the dose was being raised.4

Three limits apply to reading these as Ozempic against Zepbound. The diabetes trial tested semaglutide at 1 mg, and Ozempic also has a 2 mg dose that was not in it. The obesity trial used semaglutide at Wegovy's doses, which Ozempic does not reach. And the obesity trial was open-label, meaning people knew which drug they were taking, and was funded by Eli Lilly.3,4 The pages on Ozempic vs Mounjaro and Wegovy vs Zepbound cover each trial in full.

What did each do in its own label trials?

Each label reports what its drug did against placebo, in the people it was meant for.1,2

Trial in the labelWhoResultPlacebo
Ozempic 0.5 mg, 30 weeksType 2 diabetesHbA1c −1.4 points; weight −3.8 kg−0.1 points; −1.2 kg
Ozempic 1 mg, 30 weeksType 2 diabetesHbA1c −1.6 points; weight −4.7 kg−0.1 points; −1.2 kg
Zepbound 5 mg, 72 weeksObesity or overweight, no diabetesWeight −15.0%−3.1%
Zepbound 10 mg, 72 weeksObesity or overweight, no diabetesWeight −19.5%−3.1%
Zepbound 15 mg, 72 weeksObesity or overweight, no diabetesWeight −20.9%−3.1%
Zepbound 10 and 15 mg, 72 weeksObesity or overweight with type 2 diabetesWeight −12.8% and −14.7%−3.2%

Ozempic prescribing information, section 14, and Zepbound prescribing information, Table 2.1,2

The Ozempic trials in the label's main table were small by comparison, with about 260 people in each group.1

Ozempic's weight results are in kilograms. As a share of the average starting weight in each trial they come to 4.2% on 0.5 mg, 4.9% on 1 mg and 6.4% on 2 mg, by our arithmetic from the label's figures.1

Set next to Zepbound's 15% to 21%, that looks like a gap of three to four times. Much of it comes from differences between the trials. The Ozempic trials ran 30 to 40 weeks against 72. Their participants had type 2 diabetes, and people with diabetes lost less in Zepbound's own trials too: 12.8% and 14.7% on the doses that gave 19.5% and 20.9% without it. And Ozempic's doses stop at 2 mg, below the 2.4 mg of semaglutide that the obesity trial used.1,2,4

The fair comparison of the molecules is therefore the head-to-head trial in obesity: 20.2% against 13.7% over 72 weeks.4

The same results with placebo taken out

Part of every result belongs to the diet, the attention and the passage of time, which the placebo group measures. Subtracting it gives the part attributable to the drug.1,2

TrialDrugPlaceboDifference
Ozempic 0.5 mg, 30 weeks−3.8 kg−1.2 kg2.6 kg
Ozempic 1 mg, 30 weeks−4.7 kg−1.2 kg3.5 kg
Zepbound 5 mg, 72 weeks−15.0%−3.1%11.9 points
Zepbound 10 mg, 72 weeks−19.5%−3.1%16.4 points
Zepbound 15 mg, 72 weeks−20.9%−3.1%17.8 points
Zepbound 10 mg, with type 2 diabetes−12.8%−3.2%9.6 points
Zepbound 15 mg, with type 2 diabetes−14.7%−3.2%11.6 points

Ozempic and Zepbound prescribing information. The Ozempic differences are our subtraction; the Zepbound differences are stated in the label.1,2

The placebo groups lost little in all of these trials: 1.2 kg in Ozempic's and about 3% in Zepbound's. The gap between the products is in the drug column.1,2

How many people reached each threshold on Zepbound?

The label's main trial enrolled 2,539 adults without diabetes and reports the share who lost at least a given percentage of their weight.2 The Ozempic label has no such figures, because weight was not what its trials were built to test.

Lost at leastPlaceboZepbound 5 mg10 mg15 mg
5%34.5%85.1%88.9%90.9%
10%18.8%68.5%78.1%83.5%
15%8.8%48.0%66.6%70.6%
20%3.1%30.0%50.1%56.7%

Zepbound prescribing information, Table 2, adults without diabetes, week 72.2

In Zepbound's trial in people with type 2 diabetes the shares were lower: at least 10% was lost by 60.5% on 10 mg and 64.8% on 15 mg, and at least 20% by 21.5% and 30.8%, against 9.5% and 1.0% on placebo.2

Who was in the label trials?

Ozempic, main safety poolZepbound, main trial
People on the drug521About 1,900 of 2,539 enrolled
LengthAbout 33 weeks72 weeks
ConditionType 2 diabetes, for 8.8 years on averageObesity or overweight, no diabetes
Average at the startHbA1c 8.2%, age 56Weight about 105 kg

Ozempic prescribing information, section 6.1, and Zepbound prescribing information, section 14 and Table 2.1,2

The Zepbound trials gave every participant, placebo included, instruction on a diet with about 500 kcal a day less and counseling to be active for at least 150 minutes a week.2 Ozempic is approved as an addition to diet and exercise.1 The page on what to eat on a GLP-1 applies to both.

What do those results look like in my weight?

Enter your weight to see each trial's average loss as pounds or kilograms.

Each trial in my weightLabels and direct trial
Unit

Log your weight each week and see your own line next to these averages.

Open the app

Separate trials of different lengths in different people, apart from the last two bars, which are the two arms of one trial. The bars show trial averages, not what switching would do.

Which lowers blood sugar more?

In the one trial that compared the molecules in diabetes, tirzepatide did, by a small margin. HbA1c fell 1.9 points on semaglutide 1 mg and 2.0, 2.2 and 2.3 points on tirzepatide 5, 10 and 15 mg, from an average of 8.3% at the start.3

The approvals run the other way from what that might suggest. Ozempic is the product approved for blood sugar control. Zepbound is not: the tirzepatide product approved for type 2 diabetes is Mounjaro.1,2 The Zepbound label does say that the drug lowers blood glucose and can cause low blood sugar.2

In Ozempic's own label trial, HbA1c fell 1.4 points on 0.5 mg and 1.6 points on 1 mg over 30 weeks, against 0.1 on placebo, and in the trial of the top dose it fell 2.1 points on 2 mg against 1.9 on 1 mg.1

Which has evidence for the heart and kidneys?

Ozempic has it in its label. Two of its three approved uses rest on outcome trials in people with type 2 diabetes.1

Ozempic outcome trialWhoResult
Cardiovascular3,297 adults with type 2 diabetes at high cardiovascular risk, median 2.1 yearsMajor events in 6.6%, against 8.9% on placebo
Kidney3,533 adults with type 2 diabetes and chronic kidney diseaseKidney outcome in 18.7%, against 23.2% on placebo

Ozempic prescribing information, section 14. Hazard ratios 0.74 and 0.76.1

The cardiovascular trial counted cardiovascular death, non-fatal heart attack and non-fatal stroke. The kidney trial counted a sustained decline in kidney function, kidney failure and cardiovascular death. These are the events named in Ozempic's second and third approved uses.1

Zepbound's label has no cardiovascular or kidney indication. Its second indication is for sleep: two 52-week trials in 469 adults with obesity and moderate to severe obstructive sleep apnea, in which the drug reduced the number of breathing interruptions per hour more than placebo.2

In those sleep trials the dose was raised to 10 mg or 15 mg, whichever was the highest tolerated. One trial enrolled people who could not or would not use a PAP machine and the other people who were using one. The label adds that the trials did not study when or whether PAP therapy can be stopped.2

So the two products have gathered different kinds of proof beyond their main use. For someone with type 2 diabetes and heart or kidney disease, Ozempic's label speaks to that directly. For someone with obesity and sleep apnea, Zepbound's does.1,2

What if you have both type 2 diabetes and obesity?

Then each label has evidence in people like you. Ozempic's trials were all in type 2 diabetes: HbA1c fell 1.4 to 2.1 points depending on the dose, with 4% to 6% of body weight lost.1 Zepbound's second main trial enrolled adults with type 2 diabetes and obesity or overweight, who lost 12.8% of their weight on 10 mg and 14.7% on 15 mg over 72 weeks, against 3.2% on placebo.2

The direct trial in diabetes sits between the two: over 40 weeks, 5.7 kg on semaglutide 1 mg and 7.6 to 11.2 kg on tirzepatide, with HbA1c lower by 1.9 and by 2.0 to 2.3 points.3

What only Ozempic's label adds for this group is outcome evidence: fewer major cardiovascular events and fewer kidney events than placebo in its two outcome trials.1 Which of these considerations weighs most is a decision for the prescriber.

How do the dose ladders compare?

Both start low and step up every four weeks at the fastest. The numbers on the pens are not comparable: 1 mg of semaglutide and 10 mg of tirzepatide are doses of different drugs.1,2

OzempicZepbound
Starting dose0.25 mg for 4 weeks2.5 mg for 4 weeks
Next0.5 mg5 mg
Further steps1 mg, then 2 mg, each after at least 4 weeks, if more blood sugar control is needed2.5 mg at a time, each after at least 4 weeks
Long-term doses0.5, 1 or 2 mg5, 10 or 15 mg for weight; 10 or 15 mg for sleep apnea
Maximum2 mg15 mg
Earliest week at the top doseWeek 13Week 21

Ozempic and Zepbound prescribing information, section 2.1,2

WeeksOzempic, at the fastestZepbound, at the fastest mg
1 to 40.25 mg2.5
5 to 80.5 mg5
9 to 121 mg, if needed7.5
13 to 162 mg, if needed10
17 to 202 mg12.5
21 onward2 mg15

The earliest schedule each label allows.1,2

A person can stop climbing at any step. Ozempic's label raises the dose only when more blood sugar control is needed, and Zepbound's label names 5 mg as a long-term dose alongside 10 mg and 15 mg.1,2

Either ladder, my datesFDA labels
Drug

    Log each shot and the app keeps these dates for you.

    Open the app

    The earliest dates each label allows. Ozempic's steps to 1 mg and 2 mg are taken only if more blood sugar control is needed. The prescriber decides each step.

    The reason for a step differs. On Ozempic the label ties each increase to the need for more blood sugar control. On Zepbound it asks prescribers to consider treatment response and tolerability when choosing the long-term dose.1,2 The pages on the Ozempic and Zepbound schedules have each ladder in full.

    Which has more side effects?

    The same kinds, in the stomach and gut, on both. The rates in the two labels come from very different trials, so they describe each drug in its own setting and cannot rank them.1,2

    Stomach and gut reactionsEach label's trials
    Reaction

    Ozempic: about 33 weeks in adults with type 2 diabetes. Zepbound: 72 weeks in adults with obesity or overweight. Each drug bar belongs with its own placebo.

    ReactionOzempic trials: placebo, 0.5 mg, 1 mgZepbound trials: placebo, 5, 10, 15 mg
    Nausea6.1%, 15.8%, 20.3%8%, 25%, 29%, 28%
    Vomiting2.3%, 5%, 9.2%2%, 8%, 11%, 13%
    Diarrhea1.9%, 8.5%, 8.8%8%, 19%, 21%, 23%
    Constipation1.5%, 5%, 3.1%5%, 17%, 14%, 11%
    Stopped because of side effectsStomach and gut reactions: 0.4%, 3.1%, 3.8%Any adverse reaction: 3.4%, 4.8%, 6.3%, 6.7%

    Ozempic prescribing information, Table 1, and Zepbound prescribing information, Table 1.1,2

    Reaction by reaction

    Nausea. The most common reaction on both. Ozempic: 15.8% on 0.5 mg and 20.3% on 1 mg, against 6.1% on placebo. Zepbound: 25%, 29% and 28% on 5, 10 and 15 mg, against 8%. In the direct diabetes trial: 18% on semaglutide 1 mg and 17% to 22% on tirzepatide.1,2,3

    Vomiting. Ozempic: 5% and 9.2%, against 2.3%. Zepbound: 8%, 11% and 13%, against 2%. It rises with the dose on both, and it is the reaction both labels tie to dehydration and kidney injury when it persists.1,2

    Diarrhea. Ozempic: 8.5% and 8.8%, against 1.9%. Zepbound: 19%, 21% and 23%, against 8%. In the direct trial: 12% on semaglutide and 13% to 16% on tirzepatide.1,2,3

    Constipation. Ozempic: 5% and 3.1%, against 1.5%. Zepbound: 17%, 14% and 11%, against 5%. On both drugs it was reported less often at the higher dose.1,2

    The Zepbound figures are higher across the board, and so are several of its placebo figures: 8% of people on placebo reported diarrhea in the Zepbound trials and 1.9% in the Ozempic trials.1,2 A trial that runs 72 weeks gives each person more time to report a reaction than one that runs about 33.

    The direct trial in diabetes is the cleaner comparison. Over the same 40 weeks, nausea was reported by 18% on semaglutide 1 mg and by 17% to 22% on tirzepatide, diarrhea by 12% and 13% to 16%, and vomiting by 8% and 6% to 10%. Serious adverse events were reported by 3% on semaglutide and 5% to 7% on tirzepatide.3

    Both labels say that most nausea, vomiting and diarrhea came while the dose was being raised.1,2 The pages on Ozempic side effects and the Zepbound side effects timeline go through each label.

    Side effects outside the stomach, in each label

    ReactionOzempic trialsZepbound trials: placebo, 5, 10, 15 mg
    Reactions at the injection site0.2%2%, 6%, 8%, 8%
    FatigueMore than 0.4%3%, 5%, 6%, 7%
    DizzinessMore than 0.4%2%, 4%, 5%, 4%
    Hair lossReported after approval, no rate1%, 5%, 4%, 5%
    Heart rateUp 2 to 3 beats a minute
    Gallstones1.5% on 0.5 mg, 0.4% on 1 mg, none on placebo
    Pancreatitis7 people, 0.3 per 100 patient-years, against 0.2 on comparison treatments

    Ozempic prescribing information, section 6, and Zepbound prescribing information, Table 1.1,2

    The Zepbound trial that followed a 12-week diet program reported that 10% of people on the drug and 2% on placebo stopped because of adverse reactions.2

    Reported after approval, and in blood tests

    Both molecules have the same kinds of reports from use outside trials. The Ozempic label lists pancreatitis, ileus and intestinal obstruction, severe constipation including fecal impaction, serious allergic reactions, gallbladder inflammation, acute kidney injury, aspiration during procedures, altered skin sensations, headache and hair loss.1 The label of tirzepatide for diabetes lists pancreatitis, ileus and intestinal obstruction, severe constipation, serious allergic reactions, kidney failure, aspiration and hair loss.9 Both caution that such reports are voluntary and that their frequency cannot be reliably estimated.

    Pancreatic enzymes rise on both. On Ozempic, amylase rose by an average of 13% and lipase by 22%. On tirzepatide in the diabetes trials, amylase rose by 33% to 38% and lipase by 31% to 42%. Neither change appeared on placebo, and the tirzepatide label says the meaning of the rises is unknown without other signs of pancreatitis.1,9

    Hair loss

    It was reported by 4% to 5% of people in the Zepbound trials, against 1% on placebo.2 Ozempic's trial tables do not include it; it appears among the reports received after approval.1 At semaglutide's weight dose the Wegovy label reports 3% against 1%, and says it was associated with weight reduction.8 The page on hair loss explains the link.

    Are the warnings the same?

    Largely. Both labels carry a boxed warning about thyroid C-cell tumors, and both warn about pancreatitis, low blood sugar with insulin or a sulfonylurea, kidney injury from dehydration, severe stomach and gut reactions, allergic reactions, gallbladder disease, diabetic retinopathy and aspiration during anesthesia or deep sedation.1,2 Neither is recommended for people with severe gastroparesis.

    What the warnings ask you to watch for

    WarningWhat the Ozempic label says
    PancreatitisPersistent or severe abdominal pain, sometimes radiating to the back, with or without nausea or vomiting. If it is suspected, the drug is stopped
    Thyroid tumorsA lump in the neck, trouble swallowing, shortness of breath or persistent hoarseness
    Kidney injuryFollows dehydration from nausea, vomiting or diarrhea that persists
    GallbladderIf gallstones are suspected, gallbladder studies and follow-up
    EyesChanges in vision during treatment, in people with diabetes
    AnesthesiaTell the team before a planned operation or procedure with anesthesia or deep sedation

    Ozempic prescribing information, sections 5 and 17. The Zepbound label has warnings under the same headings.1,2

    Does either cause low blood sugar?

    Rarely alone, and more often together with insulin or a sulfonylurea.1,2

    SituationDrugPlacebo
    Ozempic alone, symptomatic at 70 mg/dL or below, 30 weeks0.5 mg1.6%1 mg3.8%0%
    Ozempic with basal insulin, same measure0.5 mg16.7%1 mg29.8%15.2%
    Zepbound in type 2 diabetes, below 54 mg/dL4.2%1.3%
    Zepbound with a sulfonylurea, below 54 mg/dL10.3%, against 2.1% without one

    Ozempic prescribing information, Table 2, and Zepbound prescribing information, section 5.7. The two labels use different thresholds.1,2

    The Ozempic label gives more detail. With basal insulin, a severe episode or one confirmed at 56 mg/dL or below was reported by 8.3% on 0.5 mg and 10.7% on 1 mg, against 5.3% on placebo. With a sulfonylurea, symptomatic episodes were reported by 17.3% and 24.4%, and severe ones by 0.8% and 1.2%.1 In the direct diabetes trial, where people took metformin and neither of those medicines, readings below 54 mg/dL were reported by 0.4% on semaglutide and 0.2% to 1.7% on tirzepatide.3

    Both labels tell prescribers that the risk may be lowered by reducing the dose of the insulin or the sulfonylurea.1,2

    Do age or kidney disease change the comparison?

    Neither label asks for a different dose. Ozempic needs no dose adjustment for reduced kidney function, and in its larger pool of trials 23.6% of the people taking it were 65 or older; the label found no general difference in safety between older and younger patients and adds that greater sensitivity in some older people cannot be ruled out.1

    For tirzepatide the Mounjaro label says the same things: no dose adjustment for reduced kidney function, and no general difference in safety among the 30.1% of trial participants who were 65 or older.9 For both drugs the practical concern with kidneys is fluid: vomiting or diarrhea that causes dehydration.

    What if a dose is late?

    The two labels give different windows.1,2

    OzempicZepbound
    Take the missed dose if it is within5 days4 days (96 hours)
    After thatSkip it and take the next dose on the usual daySkip it and take the next dose on the usual day

    Ozempic and Zepbound prescribing information, section 2.1,2

    A late dose, each labelLabel rules and model
    Days since the dose was due

    The levels come from our model, built on each label's half-life, for a settled dose. They are not blood tests.

    The rule differs by one day, and that day is where the two labels disagree: on the fifth day after a missed dose, Ozempic's label says to take it and Zepbound's says to skip it.1,2

    The longer window for Ozempic matches its longer half-life: about one week, against about five days for tirzepatide.1,2 The page on missed doses works through the days one by one.

    How long does each stay in the body?

    Semaglutide lasts longer. The Ozempic label gives it a half-life of about one week and says it remains in the circulation for about 5 weeks after the last dose.1 Tirzepatide has a half-life of about 5 days.2 By the same arithmetic of five half-lives, that is about 25 days.

    Both drugs are built to last a week. The Ozempic label attributes semaglutide's long half-life to its binding to albumin, a blood protein, which slows its clearance. The Zepbound label says tirzepatide carries a fatty acid chain that enables the same albumin binding.1,2

    This matters in three situations: side effects after stopping, a planned pregnancy and a switch from one drug to the other. The pages on how the level moves through the week and how long tirzepatide stays in your system show both curves.

    Planning a pregnancy

    The Ozempic label says to stop it at least 2 months before a planned pregnancy, because of the long time the drug takes to leave the body. The Zepbound label says to stop it when pregnancy is recognized, and tells people who use birth control pills to switch to a non-oral method or add a barrier method for 4 weeks after starting and after each dose increase, because the drug slows the emptying of the stomach.1,2 The page on tirzepatide and birth control explains that rule.

    How do they compare in daily use?

    Closely. Each is injected once a week, on the same day each week, at any time of day, with or without meals.1,2 The differences are in the hardware and the clock: an Ozempic pen holds several weekly doses, a Zepbound single-dose pen is used once, a late dose is allowed for 5 days on Ozempic and 4 on Zepbound, and people on birth control pills have a 4-week rule on Zepbound that Ozempic's label does not contain.1,2

    How do the pens and storage differ?

    An Ozempic pen is used for several weeks: the label describes single-patient-use pens that hold multiple weekly doses. Zepbound comes as single-dose pens and single-dose vials, used once, and as multi-dose vials and KwikPens that hold four doses.1,2

    Ozempic penZepbound single-dose pen or vial
    Before useIn a refrigerator, 36°F to 46°FIn a refrigerator, 36°F to 46°F
    Out of the refrigeratorAfter first use, 56 days at room temperature or refrigeratedUp to 21 days in total at up to 86°F, then discard
    FreezingDo not use if frozenDo not use if frozen

    Ozempic and Zepbound prescribing information, section 16.1,2

    The page on Zepbound storage has the rules for each form, including travel.

    What does each cost?

    With insurance that covers the product, either can cost as little as $25 a month with the manufacturer's savings card. Without coverage, both makers publish self-pay prices, and they are close.5,6

    A year of eachNov 20, 2026
    My situation
    Dose after the first months

    Log each fill and what it cost, and the app adds up your year.

    Open the app

    Thirteen four-week fills make a year. Usual dose: Ozempic up to 1 mg, Zepbound 5 mg. Highest: Ozempic 2 mg from the fourth fill, Zepbound 15 mg refilled on time. Self-pay figures are for a new patient.

    Self-pay, per fillOzempicZepbound
    Starting doses$199 for the first two fills, new patients$299 for 2.5 mg
    Usual doses$349 for 0.25, 0.5 or 1 mg$399 for 5 mg
    Higher doses$499 for 2 mg$449 for 7.5 to 15 mg, refilled within 45 days
    A first year at a usual dose$4,237$5,087
    A first year at the highest dose$5,737$5,637
    List price of one fill$1,027.51$1,087

    NovoCare, LillyDirect and TrumpRx.gov, read November 20, 2026. Year totals are our arithmetic.5,6,7

    With coverage: the two savings cards

    When a commercial plan covers the product, Novo Nordisk's offer brings Ozempic to as little as $25, taking off up to $100 a month. Lilly's card brings Zepbound to as little as $25, taking off up to $100 a month and $1,300 a year.5,6 The limits matter when a plan leaves more than $125 a month to pay: the card then covers only the first $100.

    The two price lists are built differently. Ozempic has one price up to 1 mg and an introductory price of $199 for a new patient's first two fills. Zepbound has no introductory price and three price steps by dose.5,6

    At the usual doses Ozempic is the cheaper of the two by $850 over a first year. At the top doses the order flips by $100, because Ozempic's 2 mg pen costs $499 a fill and Zepbound's higher doses hold at $449 when refilled on time.5,6

    The same prices by the week

    One fill holds four weekly doses. At the regular self-pay prices that is $87.25 a week for Ozempic up to 1 mg and $124.75 for 2 mg, against $99.75 for Zepbound 5 mg and $112.25 for its higher doses.5,6

    After the first year Ozempic loses its two $199 fills and costs $4,537 for thirteen fills at 1 mg or below, or $6,487 at 2 mg. Zepbound comes to $5,187 at 5 mg and $5,837 at the higher doses.5,6 Zepbound's $449 price depends on refilling within 45 days; a later refill costs $499 for 7.5 mg and $699 for 10 to 15 mg.6

    Both self-pay prices are a fraction of the list prices: $349 against $1,027.51 for Ozempic, and $399 or $449 against the $1,087 that TrumpRx shows as Zepbound's original price.5,7

    Price is only part of the cost. The two products are approved for different conditions, and whether a plan covers one is the plan's decision. The page on GLP-1 cost without insurance has every dose and program.

    What happens when either is stopped?

    The Zepbound label includes a trial that shows what happens to weight. Adults who had lost at least 5% in a 12-week diet program were assigned to Zepbound or placebo. Over the next 72 weeks the Zepbound group lost a further 18.4% and the placebo group regained 2.5%.2 The page on stopping Zepbound covers the withdrawal trial.

    For Ozempic the label's statement is about the drug: it remains in the circulation for about 5 weeks after the last dose.1 The page on why people stop has the reasons people give, with cost first.

    Can you switch from one to the other?

    Neither label describes a switch between semaglutide and tirzepatide. What the Zepbound label does say is that it should not be used together with any GLP-1 receptor agonist, which Ozempic is.2 A change from one to the other is therefore a stop and a start, and both labels start new patients at the lowest dose.1,2 The timing and the dose are the prescriber's decision. The page on switching from Wegovy to Zepbound shows how the two levels overlap after a change.

    Can either be used under 18?

    Not by its label. The Ozempic label says its safety and efficacy have not been established in pediatric patients, and Zepbound's approved uses are for adults.1,2 The sister brands do have approvals under 18, which the pages on Ozempic vs Wegovy and Mounjaro vs Zepbound set out.

    What can these sources not tell you?

    Three things. No trial has compared Ozempic at 2 mg with Zepbound, so the top of Ozempic's range has no direct comparison. The two direct trials were open-label, and the larger difference in weight was found in a trial funded by the maker of tirzepatide. And averages describe groups: within each trial some people lost far more and some far less, as the threshold table for Zepbound shows.2,3,4

    Neither label ranks the two drugs. Each reports its own product against placebo, in the people it was approved for.1,2

    Short answers to common questions

    Is Zepbound stronger than Ozempic?

    They are different drugs, so milligrams do not compare. In the trial that compared the molecules in obesity, tirzepatide produced 20.2% weight loss and semaglutide 13.7% over 72 weeks.

    Which is better for weight loss, Ozempic or Zepbound?

    Zepbound is the one approved for it. Ozempic is approved for type 2 diabetes. In both direct trials of the two molecules, tirzepatide led to more weight loss.

    Which is better for type 2 diabetes?

    Ozempic is the one approved for it, with cardiovascular and kidney indications as well. The tirzepatide product approved for diabetes is Mounjaro. In their direct trial, HbA1c fell 1.9 points on semaglutide 1 mg and 2.0 to 2.3 points on tirzepatide.

    Is Ozempic approved for weight loss?

    No. The semaglutide product approved for weight is Wegovy.

    Do they work the same way?

    Partly. Both activate the GLP-1 receptor. Tirzepatide also activates the GIP receptor.

    Which has fewer side effects?

    The labels cannot say, because their trials differ. In the 40-week direct trial in diabetes, nausea was reported by 18% on semaglutide 1 mg and by 17% to 22% on tirzepatide.

    Which is cheaper without insurance?

    At usual doses, Ozempic: $349 a fill against $399 for Zepbound 5 mg. At the top doses, Zepbound: $449 against $499.

    Can you take Ozempic and Zepbound together?

    No. The Zepbound label says it should not be used with any GLP-1 receptor agonist.

    Can you switch from Ozempic to Zepbound?

    The labels do not describe it. Both start new patients at their lowest dose, and the timing and dose are for the prescriber to decide.

    Which stays in the body longer?

    Ozempic. Semaglutide has a half-life of about a week and tirzepatide about 5 days.

    What if I miss a dose?

    Ozempic: take it within 5 days, otherwise skip. Zepbound: take it within 4 days, otherwise skip.

    Which protects the heart and kidneys?

    Ozempic has label indications for both, in people with type 2 diabetes. Zepbound's label has neither.

    Which one treats sleep apnea?

    Zepbound, in adults with obesity and moderate to severe obstructive sleep apnea.

    Is 2 mg of Ozempic the same as 2.5 mg of Zepbound?

    No. They are different molecules. 2 mg is Ozempic's highest dose, and 2.5 mg is Zepbound's starting dose.

    Why do people compare Ozempic with Zepbound at all?

    Because they are the best-known names of the two molecules. The matching comparisons are Ozempic with Mounjaro, both for diabetes, and Wegovy with Zepbound, both for weight.

    How much more weight loss does tirzepatide give?

    In the direct obesity trial, 6.5 percentage points more over 72 weeks: 20.2% against 13.7%. In the direct diabetes trial, 1.9 to 5.5 kg more than semaglutide 1 mg over 40 weeks, depending on the dose.

    Does Zepbound lower blood sugar?

    Yes. Its label says it lowers blood glucose and can cause low blood sugar. It is not approved for blood sugar control.

    Does Ozempic 2 mg close the gap?

    No trial has put Ozempic 2 mg against tirzepatide. In Ozempic's own trial, 2 mg produced a weight loss of about 6.4% of body weight over 40 weeks.

    Which costs more per week?

    At usual doses Zepbound: $99.75 a week for 5 mg against $87.25 for Ozempic up to 1 mg. At the top doses Ozempic: $124.75 against $112.25.

    Which has the longer pen life?

    An Ozempic pen holds several weekly doses and can be kept for 56 days after first use. A Zepbound single-dose pen is used once.

    Is one safer than the other?

    The labels carry the same boxed warning and nearly the same list of warnings. In the 40-week direct trial, serious adverse events were reported by 3% on semaglutide 1 mg and 5% to 7% on tirzepatide.

    Which is easier to stay on?

    The labels give different measures. Stomach and gut reactions ended treatment for 3.1% to 3.8% of people in the Ozempic trials. Adverse reactions of any kind ended it for 4.8% to 6.7% in the longer Zepbound trials.

    Is nausea worse on Zepbound or Ozempic?

    In the trial that tested both molecules for 40 weeks, nausea was reported by 18% on semaglutide 1 mg and by 17% to 22% on tirzepatide. The label rates are not comparable, because the Zepbound trials ran more than twice as long.

    How many people lose 20% of their weight?

    On Zepbound, 30% on 5 mg, 50.1% on 10 mg and 56.7% on 15 mg in its main trial, against 3.1% on placebo. Ozempic's label reports no such figure.

    Does either need to be taken with food?

    No. Both labels allow the injection at any time of day, with or without meals.

    Do older adults need a lower dose?

    Neither label asks for one. Both note that greater sensitivity in some older people cannot be ruled out.

    Which is approved for heart disease?

    Ozempic, to reduce major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. In its trial, events occurred in 6.6% on Ozempic and 8.9% on placebo.

    How fast can each reach its top dose?

    Ozempic in week 13 at the earliest, Zepbound in week 21.

    What does a year of each cost with coverage?

    At the $25 floor of either savings card, thirteen fills come to $325. Both cards take off at most $100 a month.

    How long did the trials run?

    Ozempic's label trials ran 30 to 40 weeks and its outcome trials about two years or more. Zepbound's main trials ran 72 weeks. The two direct trials ran 40 weeks in diabetes and 72 weeks in obesity.

    Does Zepbound come in a vial?

    Yes. Its label lists single-dose vials and multi-dose vials alongside the pens, and LillyDirect prices the vial and the KwikPen the same.

    Does either affect birth control pills?

    The Zepbound label advises a non-oral or barrier method for 4 weeks after starting and after each dose increase. The Ozempic label contains no such rule.

    Does Ozempic or Zepbound cause more hair loss?

    Hair loss was reported by 4% to 5% in the Zepbound trials, against 1% on placebo. Ozempic's trial tables do not list it. Both labels connect it with weight loss or list it among later reports.

    Is Zepbound a GLP-1?

    It acts on the GLP-1 receptor and on the GIP receptor. Ozempic acts on the GLP-1 receptor only.

    Were the direct trials blinded?

    No. Both were open-label, so participants knew which drug they were taking.

    Which brand matches which?

    Ozempic and Wegovy are semaglutide, for diabetes and for weight. Mounjaro and Zepbound are tirzepatide, for diabetes and for weight.

    Do blood tests change on these drugs?

    Pancreatic enzymes rise on both: lipase by an average of 22% on Ozempic and by 31% to 42% on tirzepatide in the diabetes trials.

    How the calculators work

    The head-to-head chart shows the two published trials that compared semaglutide with tirzepatide. The weight calculator multiplies your weight by each trial's average loss as a share of starting weight: 4.9% and 6.4% for Ozempic 1 mg and 2 mg, which we worked out from the label's kilograms and average starting weights; the percentages the Zepbound label states; and the two arms of the direct obesity trial.

    The late-dose block applies each label's missed-dose rule and shows the level of each drug in our model: one compartment, with half-lives of 7 days for semaglutide and 5 days for tirzepatide. The calendar places each label's dose steps at 4-week intervals from the date you enter. The reaction chart sets Table 1 of each label side by side. The cost calculator adds 13 four-week fills at the prices the manufacturers published on November 20, 2026.

    The label trials differ in length, population and purpose, and only the two direct trials compare the molecules under the same conditions. One of those tested semaglutide at 1 mg and the other at Wegovy's doses, so neither is a trial of Ozempic at its top dose against Zepbound.

    Sources

    1. OZEMPIC (semaglutide) injection prescribing information, NDA 209637/S-039, revised May 2026. U.S. Food and Drug Administration; sections 1, 2, 5, 6.1, 8, 12, 14 and 16. accessdata.fda.gov
    2. ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; sections 1, 2, 5, 6.1, 7, 8, 12, 14 and 16. accessdata.fda.gov
    3. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med 2021;385:503-515. doi:10.1056/NEJMoa2107519
    4. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med 2025;393:26-36. doi:10.1056/NEJMoa2416394
    5. Novo Nordisk. NovoCare: Ozempic list price; Ozempic savings and self-pay offers. Read November 20, 2026. novocare.com
    6. Eli Lilly and Company. LillyDirect: Zepbound self-pay prices; Zepbound coverage and savings, savings card terms. Read November 20, 2026. lilly.com
    7. TrumpRx.gov. Listings for Ozempic and Zepbound. Read November 20, 2026. trumprx.gov
    8. WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; sections 1 and 14. accessdata.fda.gov
    9. MOUNJARO (tirzepatide) injection prescribing information, NDA 215866/S-052, revised April 2026. U.S. Food and Drug Administration; sections 1 and 14. accessdata.fda.gov

    Related analyses

    Log your doses and weight, whichever name is on the box.

    Open Dose Insider